Nicotine receptor partial agonists for smoking cessation.
By K. Lin. American Family Physician, 2011
878 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/e80738946fca66ccbf2e2a18b2ff5851c099f28c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- I. Graham
- T. Ivanova
- J. Perk
- M. Piepoli
- S. Agewall
- U. Corrà
- A. Hoes
- M. Tendera
Citations in the corpus
- 2016 European Guidelines on cardiovascular disease prevention in clinical practice (2016, background): “Overall, NRT and bupropion help 80% more people to quit than placebo; this means that for every 10 people who quit with placebo, 18 could be expected to quit with NRT or with bupropion.(285)”
- Tobacco smoking: Health impact, prevalence, correlates and interventions (2017, background): “Where it is licensed for sale, cytisine is less than 1/10th the cost of other smoking cessation medications (Cahill et al., 2016).”
- ESH / ESC Guidelines for the management of arterial hypertension (2013, background): “Relapse prevention is a cornerstone in fighting nicotine addiction but the field is inadequately studiedand existing evidence is disappointing.(388) There is in-”
- European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) (2012, unknown): “Trials suggested a modest benefit of varenicline over NRT and bupropion.(258,261) Side effects are rare, but, due to links with serious adverse events, including depressed mood, agitation, and suicidal thoughts, a psychiatric history and suicide risk assessment should be taken before prescription.”
- 2016 European Guidelines on cardiovascular disease prevention in clinical practice (2017, unknown): “could be expected to quit with NRT or with bupropion [285].”
- 2016 European Guidelines on cardiovascular disease prevention in clinical practice. (2016, background): “Overall, NRT and bupropion help 80% more people to quit than placebo; this means that for every 10 people who quit with placebo, 18 could be expected to quit with NRT or with bupropion.(285)”
- Systematic integration of biomedical knowledge prioritizes drugs for repurposing (2017, background): “Cytisine is widely used in Eastern Europe for smoking cessation due to its availability at a fraction of the cost of other pharmaceutical options (Cahill et al., 2016).”